Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Canada / NCT05070845
Recruiting Phase 2

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

NCT05070845 · tracked via the Priya Life Science Canada tracker
Sponsor
Pfizer
Phase
Phase 2
Started
2022-02-02
Last updated
2026-05-12

Condition(s) studied

Primary Immune Thrombocytopenia

Investigational drug(s) / intervention(s)

PF-06835375

PF-06835375: CXCR5 inhibitor

Study summary

This is a Phase 2, open-label, multicenter, multiple subcutaneous injection, safety and efficacy study of PF-06835375 in adult participants with primary immune thrombocytopenia (ITP). This study will focus on participants with persistent (\>3 months and ≤12 months), or chronic (\>12 months) ITP

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of Primary ITP. Ongoing ITP (platelet counts \<50 x 109/L) \[No severe bleeding within 1 month or during screening\] AND Persistent ITP (3 to 12 months) or Chronic ITP \>12 months Exclusion Criteria: * Bleeding event according to the WHO grading scale ≥2 occurring ≤4 weeks prior to screen OR a current bleeding event that, in the opinion of the investigator, requires treatment with standard of care therapy OR require blood or blood products during screening * Splenectomy within 3 months of randomization or planned during the study duration.

Primary outcome measure(s)

Trial sites (31)

FacilityCityRegionStatus
East Carolina University Greenville North Carolina Recruiting
Liverpool Hospital Liverpool New South Wales Recruiting
South West Radiology Liverpool New South Wales Recruiting
Slade Pharmacy Mount Kuring-Gai New South Wales Recruiting
Calvary Mater Newcastle Waratah New South Wales Recruiting
Flinders Medical Centre Bedford Park South Australia Recruiting
ICON Cancer Centre - Kurralta Park Kurralta Park South Australia Recruiting
The Alfred Hospital Melbourne Victoria Recruiting
Royal Perth Hospital Perth Western Australia Recruiting
Unity Health Toronto, St. Michael's Hospital Toronto Ontario Recruiting
McGill University Health Centre Montreal Quebec Recruiting
Fakultni nemocnice Hradec Kralove Hradec Králové Czechia Recruiting
Fakultni nemocnice Ostrava Ostrava - Poruba Czechia Recruiting
Fakultni nemocnice Kralovske Vinohrady Prague Czechia Recruiting
Vseobecna fakultni nemocnice v Praze Prague Czechia Recruiting
Pécsi Tudományegyetem Klinikai Központ Pécs Baranya Active Not Recruiting
Somogy Megyei Kaposi Mór Oktató Kórház Kaposvár Somogy County Recruiting
Semmelweis University Budapest Hungary Recruiting
Petz Aladár Egyetemi Oktató Kórház Győr Hungary Recruiting
Tolna Varmegyei Balassa Janos Korhaz Szekszárd Hungary Not Yet Recruiting
Komárom-Esztergom Vármegyei Szent Borbála Kórház Tatabánya Hungary Not Yet Recruiting
AIDPORT Sp. z o.o. Skórzewo Greater Poland Voivodeship Recruiting
InterHem Bialystok Poland Active Not Recruiting
Klinika Hematologii i Transplantologii Uniwersyteckie Centrum Kliniczne Gdansk Poland Active Not Recruiting
Pratia Onkologia Katowice Katowice Poland Recruiting
Uniwersytecki Szpital Kliniczny w Poznaniu Poznan Poland Active Not Recruiting
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu Wroclaw Poland Recruiting
Addenbrooke's Hospital Cambridge Cambridgeshire Recruiting
Derriford Hospital Plymouth Devon Recruiting
The Royal Cornwall Hospital Truro England Recruiting
Hammersmith Hospital London United Kingdom Recruiting

More Pfizer trials in Canada

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B Active, not recruiting
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine Recruiting
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC Active, not recruiting
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) Active, not recruiting
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05070845 on ClinicalTrials.gov ↗ ← All trials in Canada